Tag
A cluster RCT in Brazil found that a digitally enabled quality improvement intervention modestly reduced LDL-C and increased treatment intensification in ASCVD patients, but a care gap remained.
The SEMA-VR CardioLink-15 trial demonstrates that semaglutide shifts bone marrow-derived progenitor cells toward an anti-inflammatory, pro-regenerative profile, potentially enhancing endogenous vessel repair in high-risk cardiovascular pati
A massive cohort study of 245,388 US adults reveals that 1 in 287 carries a familial hypercholesterolemia mutation. Despite high risks for premature heart disease, most carriers remain undertreated, with fewer than 20% of those with establi
A large-scale nationwide study reveals that individuals with atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction and stroke, face a 43% higher risk of suicide. The risk nearly doubles for those suffering from bot
A prespecified analysis of the FOURIER trial reveals that patients with obesity and atherosclerotic cardiovascular disease experience significantly higher absolute and relative risk reductions with evolocumab, particularly those with a BMI
A longitudinal study from the Dallas Heart Study identifies calprotectin as a significant, independent predictor of ASCVD events, linking neutrophil activation to endothelial dysfunction and increased cardiovascular risk across diverse popu
This review synthesizes evidence on the performance of AHA PREVENT equations in individuals with elevated lipoprotein(a), emphasizing its independent risk association and potential to enhance personalized ASCVD risk prediction.
